Member Info for WeTookPelham

...paid just towards the close over on Aquis, which I had forgotten all about.

...just to add to previous post, I guess the needle free approach is yet another selling point/USP so why not perhaps.

Nice find.

IMO it's interesting the slant of recent media and posts by Scancell themselves is focused on the needle free delivery method rather than the more important s&n/universal vaccine angle?

But either way a story in The Telegraph is always a good thing IMO. Also, is it interesting that the story has happened so quick off the bat this time? I.e. the RNS announced only this morning. Can't read the article but can we assume this is Scancell driven hence the speed?

Fantastic summary by Albert Arthur. As mentioned on here, forget who said but the Pharmajet news today is another big and important tick box crossed off.

"All ducks lining up nicely" indeed.

Ok hasiba, trades/SP, you say tomato etc....but whatever, good luck with your trading of the share.

I think the excitement was around the progress this news specifically about the pharmajet partnership inferred with regards to trials now moving forward. I think you're the only one who mentioned the SP?

Hasiba, you've actually categorically stated earlier you want to trade the share today, so these doomie posts are a bit too obvious/on the nose. You're better than that.

Can we assume the pharmajet will now also be used for SCIB?

Great news IMO. An established and proven product.
So it seems the pharmajet product actually improves the vaccine effectiveness?

Interesting and big name partners too:
https://pharmajet.com/partner-with-us/

I'm with you Keiny1! I also would prefer a full takeover/partnership sooner rather than later.

"Both systems are available commercially hence my thoughts they will be proprietary."
Reassuring to hear both systems are commercially available, rather than a new experimental technique, IMO it removes any potential delay. Wonder why no names yet though?

https://mobile.twitter.com/scancellpharma/status/1425554329939947529

Video has been posted on the Scancell Twitter. Good to see some consistent posting.

Hopefully a Lindy Durrant "soon" actually means soon, and not a Cliff Holloway "soon"!

I'm actually feeling a lot more comfortable since she became CEO either way.

...Kind of out of the blue. Buys?

Reading it again perhaps the super referred to the very wide scope of the vaccine, rather than to sensational?

https://www.dailymail.co.uk/health/article-9853221/The-super-universal-vaccine-fight-coronavirus.html

"Culturally and strategically Biontech seems a perfect fit now Lindy is CEO with the history of previous collaborations."

Perfectly and succinctly put.

RE press coverage, this seems similar to the time the sky news coverage and then it went crazy in the rest of the media. Last time it was "universal vaccine", now it's "Super universal vaccine", do we think this new phrase was instigated by Scancell themselves or by the Daily Mail reporter?

Oh and just IMO the international articles I think may be the Daily Mail article being syndicated?

https://www.barrons.com/articles/biontech-stock-earnings-vaccine-booster-51628519985

"BioNTEch also signaled that it plans to pursue mergers and acquisitions, as well as licensing of products and strategic collaborations, to boost its pipeline of cancer drugs."

https://www.oxfordtechnologyvct.com/admin/jscripts/tiny_mce/plugins/filemanager/files/news/OT1%20strategy%20July%202021%20at%2027Jul%20v4.pdf

"? Scancell, valued at £1.15m in May. Listed on AIM. Substantial share price movement during the
course of the last 18 months which you will all be aware of. Working on a Covid vaccine, but we
see cancer immunotherapy technology as the core of the ‘risk adjusted’ value proposition.
Scancell’s share price (bid) was 22.5p at 28 February 2021 and 19.5p on 31 March 2021"

"OT1 is the oldest of the four Oxford VCTs. The portfolio is relatively stable, and has some
substantial upside potential. OT1 has at times been seen as a ‘Scancell vehicle’, and it is true to say
that of all the companies in the portfolio, it has the greatest chance of creating a ‘knock-out’ return
based on its cancer immunotherapy technologies and – possibly – a Covid vaccine."

It was really bugging me so had to look through my posting history, biilbrown had posted a link:

"WeTookPelham
RE: scancell25 Jul 2021 14:50
RE Needle free - wasn't there something about a patch? Ah yes, i rememeber this now about MICRONEEDLE PATCHES and
MICROARRAY PATCHES.

"billbrown
SKIN VACCINATION SUMMIT 202113-15 September 2021, Royal College of Physicians of Edinburgh, Edinburg15 Jul '21
http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=597&Itemid=1086
SESSION 4:SESSION 6:
DELIVERY,SESSION 8:
DEVICES
MICRONEEDLE PATCHES,SESSION 5:
MICROARRAY PATCHES
‘Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells, relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells’
Victoria A. Brentville1, Rachael L. Metheringham1, Ian Daniels1, Suha Atabani2, Peter Symonds1, Katherine W. Cook1, Ruhul Choudhury1, Poonam Vaghela1, Mohamed Gijon1, Ghislaine Meiners3, Willem-Jan Krebber3, Cornelis J. Melief3,4 and Lindy G. Durrant1,2
(1 Scancell Limited Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK; 2 Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK)"

Edit, just your post now Crumbs. But worth re-posting BillBrowns post IMO."

If you go to that link you will see the Scancell talk sanwiched between the talks about:

"SESSION 7:
VACCINES & VACCINATION
Moderator: Esther de Jong
(University of Amsterdam, Amsterdam, The Netherlands)

‘ZIKA skin vaccination’
Jacob Beaver and Ioanna Skountzou
(Emory University, Atlanta, Georgia, USA)

‘Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells, relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells’
Victoria A. Brentville1, Rachael L. Metheringham1, Ian Daniels1, Suha Atabani2, Peter Symonds1, Katherine W. Cook1, Ruhul Choudhury1, Poonam Vaghela1, Mohamed Gijon1, Ghislaine Meiners3, Willem-Jan Krebber3, Cornelis J. Melief3,4 and Lindy G. Durrant1,2
(1 Scancell Limited Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK; 2 Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK)

‘A thermostable microneedle patch for tetanus toxoid vaccination’
Andrey V. Romanyuk1, Ioanna Skountzou2 and Mark R. Prausnitz1
(1 School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA; 2 Department of Microbiology & Immunology, Emory University, Atlanta, Georgia, USA)

‘Patchless administration of canine influenza vaccine on dog’s ear without hair removal using insertion-responsive microneedles (IRMNs)’
In-Jeong Choi1§, Woonsung Na2§, Myun-Hwan Ahn1, Aram Kang3, Seong-O Choi1, Seung-Ki Baek1, Daesub Song3* and Jung-Hwan Park4*
(1 QuadMedicine R&D Centre, QuadMedicine, Inc., Seongnam,"

Now i assume there w